Law firm investigating potential securities law violations and fiduciary duty breaches for several companies involved in merger and acquisition transactions.

The choroidal neovascularization therapeutics market is projected to grow significantly between 2025-2034, driven by rising AMD prevalence, technological advancements, and emerging gene therapies targeting vision preservation.

Law firm investigating potential securities law violations and fiduciary duty breaches for three companies involved in merger and acquisition transactions.

Eli Lilly announced an acquisition of Adverum Biotechnologies for up to $12.47 per share, focusing on Ixo-vec, a promising gene therapy for wet age-related macular degeneration that could transform treatment from repeated injections to a one-time therapy.

The global ophthalmology drugs market is expected to grow from $19.52 billion in 2025 to $26.28 billion by 2030, driven by aging populations, technological innovations, and increasing prevalence of vision-threatening diseases.